Pfizer and BioNTech – who have said they can prepare a new, Omicron-targeted version of Comirnaty within a matter of weeks if necessary – released new data this morning that it says showed a ...

According to Pfizer/BioNTech, preclinical data has shown that a booster dose with the BA.4/BA.5-adapted bivalent vaccine generated a strong neutralising antibody response against Omicron BA.1, BA ...

2 and KP.3 are predominant. Since August this year, the vaccine named Comirnaty omicron JN.1 from BioNTech/Pfizer, which has ...

Following the EC decision, Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine will ship to European Union (EU) member states that have specifically ordered this formulation. The CHMP ...

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

1-lineage omicron variants of the coronavirus, or SARS-CoV-2. The options include the mRNA vaccines from Pfizer/BioNTech and ...

in which Mr Bourla had been discussing high infection rates with Omicron. A Pfizer representative clarified he had been referring to research suggesting while "two doses of [Pfizer-BioNTech's ...

Experiments by Pfizer-BioNTech have shown a third dose massively boosts levels of neutralising antibodies. Results suggest that three doses fare as well against Omicron as two doses did against ...

Opinions expressed by Forbes Contributors are their own. Dave Wessner is a virologist who covers infectious diseases. In the continuing effort to mitigate the effects of Covid-19, the U.S. Food ...

Bogoch says the latest vaccine was designed for a sublineage of Omicron called KP.2, which began circulating several months ...

Este artículo estará disponible en español en El Tiempo Latino. Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall ...

A new variant of COVID called XEC — a combination of two Omicron subvariants — is spreading in the middle of flu season.